Research Commentary
A healing paper is not a reason to buy a vial
The fastest way to wreck a research journal is to end every preclinical summary with a store. This site will not do that.
Peptide research is full of papers that are genuinely interesting and easy to misuse. A rat tendon heals faster. A cell migrates. A transcription panel shifts. Each of those findings can be summarized fairly, with the model and the limit left intact. The misuse begins in the last paragraph, when the summary turns and says the finding is why a reader should purchase something.
The BPC-157 literature is the clearest example
The animal work is extensive. The 2019 musculoskeletal review and the later orthopaedic systematic review both say so, and both also say the human evidence is not there yet. A journal that quotes the healing curves and then links a 10 mg vial has decided the second fact does not matter. Readers notice. So do regulators, clinicians, and anyone who came for the paper rather than the shop.
The rule on this site
NuLife is a research-supply catalog. It is not a co-author. This journal mentions a commercial listing only when the listing itself is part of the point being made, which is rare, and the mention says the listing is not evidence. Most articles have no catalog link at all. If a study is strong, the DOI is the ending. If a study is weak, the limitation is the ending. A checkout button is neither.